DBV Technologies S.A. (DBVT) Stock Price & Analysis
DBV Technologies S.A. (DBVT) closed at USD 9.11 on Thursday, October 15, 2026, up 2.71% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 8.87; the Oct 15, 2026 session ranged USD 8.85–9.21 on volume of 432,283 shares. Market capitalization is $572.55M, with a 52-week range of USD 8.85–26.19 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DBVT.md
Key facts (DBVT)
- Analysts: Buy (mean 2.14 on a 1–5 scale) (7 analysts), mean target USD 38.69 (range 5.71–54.5).
- Total return with dividends: 1Y -46.4% vs S&P 500 +18.1%; 5Y -14.1% vs S&P 500 +85.1%.
- Next earnings: 2026-10-28, EPS estimate USD -0.15, revenue estimate $582K.
Analysts (DBVT)
Consensus Buy (mean 2.14 on a 1–5 scale), 7 analysts; mean target USD 38.69 (low 5.71, high 54.5).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-30 | Citizens | Target raised | Market Outperform | $47 → $55 |
Total return (dividends reinvested) (DBVT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -46.4% | -14.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -46.5% | -3.0% |
| Volatility (annualized) | 68.6% | 121.5% |
| Max drawdown | -63.9% (Jan 2026→Oct 2026) | -95.8% (Oct 2021→Nov 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 9.11 |
|---|---|
| Change | ▲ 2.71% (up) |
| Previous Close | USD 8.87 |
| Open | USD 8.87 |
| Day Range | USD 8.85 – 9.21 |
| 52-Week Range | USD 8.85 – 26.19 |
| Volume | 432,283 shares |
| Market Cap | $572.55M |
| Exchange | NCM |
Technical Analysis (DBVT)
Nexqual's technical model rates DBVT "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.77 (oversold) |
| vs SMA50 | Below (USD 12.5) |
| MACD | -1.02 (negative) |
Analyst Ratings (DBVT)
Wall Street analysts rate DBVT "Buy" based on 7 analysts, with a mean price target of USD 38.69 (range USD 5.71–54.5), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 38.69 |
| High Target | USD 54.5 |
| Low Target | USD 5.71 |
| Buy / Hold / Sell | 6 / 0 / 1 |
Earnings (DBVT)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $581,620 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.1 vs est -0.09 ▼ miss |
| 2026-03-31 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-12-31 | USD -0.2 vs est -0.19 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.29 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (DBVT)
| Total Revenue | $5.04M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -53.30% |
| Gross Margin | +100.00% |
| Operating Margin | -7228.57% |
| Profit Margin | +0.00% |
| ROE | -142.68% |
| Debt / Equity | 0.05 |
| Current Ratio | 3.72 |
| Total Cash | $174.90M |
| Total Debt | $7.70M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (DBVT)
Nexqual rates DBV Technologies S.A.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +26% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $175M cash vs $8M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$169M (TTM) |
| Efficiency | Critical — ROE -143%, ROA -60.6% |
Ownership (DBVT)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +41.66% |
| Shares Outstanding | 62.85M |
| Float | 31.89M |
| Short % of Float | +1.79% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (DBVT)
DBV Technologies S.A. is led by Daniel Tassé (age 65), CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Director | Daniel Tassé (age 65) |
|---|---|
| Chief Financial Officer | Virginie Simone Jeanine Verrechia Boucinha (age 56) |
Major Backers & Investors (DBVT)
Notable institutional backers of DBV Technologies S.A. include MPM Bioimpact LLC, Artisan Partners Limited Partnership, Siren, L.L.C., according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MPM Bioimpact LLC | 5.83% |
| Artisan Partners Limited Partnership | 3.52% |
| Siren, L.L.C. | 2.95% |
| Vivo Capital, LLC | 2.93% |
| Perceptive Advisors Llc | 2.63% |
| Baker Bros. Advisors, LP | 2.32% |
| UBS Group AG | 2.09% |
| Morgan Stanley | 1.52% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt